APO Research
Talk to an analyst

APO RESEARCH · REPORT

Large Molecule Drugs CDMO

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Large Molecule Drugs CDMO Market Analysis and Forecast 2026-2032

1 May 2026216 pages

Choose your research edition.

Industry ResearchLarge Molecule Drugs CDMO Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Large Molecule Drugs CDMO Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Large Molecule Drugs CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Large Molecule Drugs CDMO Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Large Molecule Drugs CDMO Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global Large Molecule Drugs CDMO market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Large Molecule Drugs CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Large Molecule Drugs CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Large Molecule Drugs CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Large Molecule Drugs CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Large Molecule Drugs CDMO include Patheon, Eurofins Scientific, Samsung Biologics, Catalent, Inc., Rentschler Biopharma SE, AGC Biologics, Recipharm AB, Siegfried Holding AG and FUJIFILM Diosynth Biotechnologies, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Large Molecule Drugs CDMO, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Large Molecule Drugs CDMO, also provides the revenue of main regions and countries. Of the upcoming market potential for Large Molecule Drugs CDMO, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Large Molecule Drugs CDMO revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Large Molecule Drugs CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Large Molecule Drugs CDMO revenue, projected growth trends, production technology, application and end-user industry.

Large Molecule Drugs CDMO Segment by Company

Patheon

Eurofins Scientific

Samsung Biologics

Catalent, Inc.

Rentschler Biopharma SE

AGC Biologics

Recipharm AB

Siegfried Holding AG

FUJIFILM Diosynth Biotechnologies

Scorpius

Ardena

Alcami

Cytiva

Thermo Fisher Scientific

Large Molecule Drugs CDMO Segment by Type

Cell Line Development

Large Molecule Drug Substance Development

Large Molecule Drugs CDMO Segment by Application

Biological Technology

Clinical

Pharmaceutical

Others

Large Molecule Drugs CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Large Molecule Drugs CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Large Molecule Drugs CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Large Molecule Drugs CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Large Molecule Drugs CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Large Molecule Drugs CDMO company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Large Molecule Drugs CDMO revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Large Molecule Drugs CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Cell Line Development Major Player Table 3. Large Molecule Drug Substance Development Major Player Table 4. Global Large Molecule Drugs CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Biological Technology Major Player Table 6. Clinical Major Player Table 7. Pharmaceutical Major Player Table 8. Others Major Player Table 9. Large Molecule Drugs CDMO Industry Trends Table 10. Large Molecule Drugs CDMO Industry Drivers Table 11. Large Molecule Drugs CDMO Industry Opportunities and Challenges Table 12. Large Molecule Drugs CDMO Industry Restraints Table 13. Global Large Molecule Drugs CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Large Molecule Drugs CDMO Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Large Molecule Drugs CDMO Market Share by Region (2021-2026) Table 16. Global Large Molecule Drugs CDMO Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Large Molecule Drugs CDMO Market Share by Region (2027-2032) Table 18. Global Large Molecule Drugs CDMO Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Large Molecule Drugs CDMO Revenue Market Share by Players (2021-2026) Table 20. Global Large Molecule Drugs CDMO Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Large Molecule Drugs CDMO Key Players Headquarters & Area Served Table 22. Global Large Molecule Drugs CDMO Players, Product Type & Application Table 23. Global Large Molecule Drugs CDMO Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Large Molecule Drugs CDMO by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Large Molecule Drugs CDMO Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Large Molecule Drugs CDMO Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Large Molecule Drugs CDMO Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Large Molecule Drugs CDMO Revenue Market Share by Type (2021-2026) Table 30. Global Large Molecule Drugs CDMO Revenue Market Share by Type (2027-2032) Table 31. Global Large Molecule Drugs CDMO Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Large Molecule Drugs CDMO Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Large Molecule Drugs CDMO Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Large Molecule Drugs CDMO Revenue Market Share by Application (2021-2026) Table 35. Global Large Molecule Drugs CDMO Revenue Market Share by Application (2027-2032) Table 36. Patheon Company Information Table 37. Patheon Business Overview Table 38. Patheon Large Molecule Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Patheon Large Molecule Drugs CDMO Product Portfolio Table 40. Patheon Recent Development Table 41. Eurofins Scientific Company Information Table 42. Eurofins Scientific Business Overview Table 43. Eurofins Scientific Large Molecule Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Eurofins Scientific Large Molecule Drugs CDMO Product Portfolio Table 45. Eurofins Scientific Recent Development Table 46. Samsung Biologics Company Information Table 47. Samsung Biologics Business Overview Table 48. Samsung Biologics Large Molecule Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Samsung Biologics Large Molecule Drugs CDMO Product Portfolio Table 50. Samsung Biologics Recent Development Table 51. Catalent, Inc. Company Information Table 52. Catalent, Inc. Business Overview Table 53. Catalent, Inc. Large Molecule Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Catalent, Inc. Large Molecule Drugs CDMO Product Portfolio Table 55. Catalent, Inc. Recent Development Table 56. Rentschler Biopharma SE Company Information Table 57. Rentschler Biopharma SE Business Overview Table 58. Rentschler Biopharma SE Large Molecule Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Rentschler Biopharma SE Large Molecule Drugs CDMO Product Portfolio Table 60. Rentschler Biopharma SE Recent Development Table 61. AGC Biologics Company Information Table 62. AGC Biologics Business Overview Table 63. AGC Biologics Large Molecule Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. AGC Biologics Large Molecule Drugs CDMO Product Portfolio Table 65. AGC Biologics Recent Development Table 66. Recipharm AB Company Information Table 67. Recipharm AB Business Overview Table 68. Recipharm AB Large Molecule Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Recipharm AB Large Molecule Drugs CDMO Product Portfolio Table 70. Recipharm AB Recent Development Table 71. Siegfried Holding AG Company Information Table 72. Siegfried Holding AG Business Overview Table 73. Siegfried Holding AG Large Molecule Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Siegfried Holding AG Large Molecule Drugs CDMO Product Portfolio Table 75. Siegfried Holding AG Recent Development Table 76. FUJIFILM Diosynth Biotechnologies Company Information Table 77. FUJIFILM Diosynth Biotechnologies Business Overview Table 78. FUJIFILM Diosynth Biotechnologies Large Molecule Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. FUJIFILM Diosynth Biotechnologies Large Molecule Drugs CDMO Product Portfolio Table 80. FUJIFILM Diosynth Biotechnologies Recent Development Table 81. Scorpius Company Information Table 82. Scorpius Business Overview Table 83. Scorpius Large Molecule Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Scorpius Large Molecule Drugs CDMO Product Portfolio Table 85. Scorpius Recent Development Table 86. Ardena Company Information Table 87. Ardena Business Overview Table 88. Ardena Large Molecule Drugs CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. Ardena Large Molecule Drugs CDMO Product Portfolio Table 90. Ardena Recent Development Table 91. Alcami Company Information Table 92. Alcami Business Overview Table 93. Alcami Large Molecule Drugs CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Alcami Large Molecule Drugs CDMO Product Portfolio Table 95. Alcami Recent Development Table 96. Cytiva Company Information Table 97. Cytiva Business Overview Table 98. Cytiva Large Molecule Drugs CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Cytiva Large Molecule Drugs CDMO Product Portfolio Table 100. Cytiva Recent Development Table 101. Thermo Fisher Scientific Company Information Table 102. Thermo Fisher Scientific Business Overview Table 103. Thermo Fisher Scientific Large Molecule Drugs CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Thermo Fisher Scientific Large Molecule Drugs CDMO Product Portfolio Table 105. Thermo Fisher Scientific Recent Development Table 106. North America Large Molecule Drugs CDMO Revenue by Type (2021-2026) & (US$ Million) Table 107. North America Large Molecule Drugs CDMO Revenue by Type (2027-2032) & (US$ Million) Table 108. North America Large Molecule Drugs CDMO Revenue by Application (2021-2026) & (US$ Million) Table 109. North America Large Molecule Drugs CDMO Revenue by Application (2027-2032) & (US$ Million) Table 110. North America Large Molecule Drugs CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 111. North America Large Molecule Drugs CDMO Revenue by Country (2021-2026) & (US$ Million) Table 112. North America Large Molecule Drugs CDMO Revenue by Country (US$ Million) & (2027-2032) Table 113. Europe Large Molecule Drugs CDMO Revenue by Type (2021-2026) & (US$ Million) Table 114. Europe Large Molecule Drugs CDMO Revenue by Type (2027-2032) & (US$ Million) Table 115. Europe Large Molecule Drugs CDMO Revenue by Application (2021-2026) & (US$ Million) Table 116. Europe Large Molecule Drugs CDMO Revenue by Application (2027-2032) & (US$ Million) Table 117. Europe Large Molecule Drugs CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 118. Europe Large Molecule Drugs CDMO Revenue by Country (2021-2026) & (US$ Million) Table 119. Europe Large Molecule Drugs CDMO Revenue by Country (US$ Million) & (2027-2032) Table 120. China Large Molecule Drugs CDMO Revenue by Type (2021-2026) & (US$ Million) Table 121. China Large Molecule Drugs CDMO Revenue by Type (2027-2032) & (US$ Million) Table 122. China Large Molecule Drugs CDMO Revenue by Application (2021-2026) & (US$ Million) Table 123. China Large Molecule Drugs CDMO Revenue by Application (2027-2032) & (US$ Million) Table 124. Asia Large Molecule Drugs CDMO Revenue by Type (2021-2026) & (US$ Million) Table 125. Asia Large Molecule Drugs CDMO Revenue by Type (2027-2032) & (US$ Million) Table 126. Asia Large Molecule Drugs CDMO Revenue by Application (2021-2026) & (US$ Million) Table 127. Asia Large Molecule Drugs CDMO Revenue by Application (2027-2032) & (US$ Million) Table 128. Asia Large Molecule Drugs CDMO Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 129. Asia Large Molecule Drugs CDMO Revenue by Region (US$ Million) & (2021-2026) Table 130. Asia Large Molecule Drugs CDMO Revenue by Region (US$ Million) & (2027-2032) Table 131. SAMEA Large Molecule Drugs CDMO Revenue by Type (2021-2026) & (US$ Million) Table 132. SAMEA Large Molecule Drugs CDMO Revenue by Type (2027-2032) & (US$ Million) Table 133. SAMEA Large Molecule Drugs CDMO Revenue by Application (2021-2026) & (US$ Million) Table 134. SAMEA Large Molecule Drugs CDMO Revenue by Application (2027-2032) & (US$ Million) Table 135. SAMEA Large Molecule Drugs CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 136. SAMEA Large Molecule Drugs CDMO Revenue by Country (2021-2026) & (US$ Million) Table 137. SAMEA Large Molecule Drugs CDMO Revenue by Country (US$ Million) & (2027-2032) Table 138. Research Programs/Design for This Report Table 139. Authors List of This Report Table 140. Secondary Sources Table 141. Primary Sources List of Figures Figure 1. Large Molecule Drugs CDMO Image Figure 2. Global Large Molecule Drugs CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Large Molecule Drugs CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 4. Cell Line Development Image Figure 5. Large Molecule Drug Substance Development Image Figure 6. Global Large Molecule Drugs CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Large Molecule Drugs CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 8. Biological Technology Image Figure 9. Clinical Image Figure 10. Pharmaceutical Image Figure 11. Others Image Figure 12. Global Large Molecule Drugs CDMO Market Size (US$ Million) & (2021-2032) Figure 13. Global Large Molecule Drugs CDMO Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Large Molecule Drugs CDMO Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Large Molecule Drugs CDMO Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Large Molecule Drugs CDMO Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Large Molecule Drugs CDMO Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Large Molecule Drugs CDMO Revenue Market Share by Type (2021-2032) Figure 20. Global Large Molecule Drugs CDMO Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Large Molecule Drugs CDMO Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Large Molecule Drugs CDMO Revenue Market Share by Application (2021-2032) Figure 23. North America Large Molecule Drugs CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Large Molecule Drugs CDMO Revenue Share by Type (2021-2032) Figure 25. North America Large Molecule Drugs CDMO Revenue Share by Application (2021-2032) Figure 26. North America Large Molecule Drugs CDMO Revenue Share by Country (2021-2032) Figure 27. United States Large Molecule Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Large Molecule Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Large Molecule Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Large Molecule Drugs CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Large Molecule Drugs CDMO Revenue Share by Type (2021-2032) Figure 32. Europe Large Molecule Drugs CDMO Revenue Share by Application (2021-2032) Figure 33. Europe Large Molecule Drugs CDMO Revenue Share by Country (2021-2032) Figure 34. Germany Large Molecule Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Large Molecule Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Large Molecule Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Large Molecule Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Large Molecule Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Large Molecule Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Large Molecule Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Large Molecule Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Large Molecule Drugs CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Large Molecule Drugs CDMO Revenue Share by Type (2021-2032) Figure 44. China Large Molecule Drugs CDMO Revenue Share by Application (2021-2032) Figure 45. Asia Large Molecule Drugs CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Large Molecule Drugs CDMO Revenue Share by Type (2021-2032) Figure 47. Asia Large Molecule Drugs CDMO Revenue Share by Application (2021-2032) Figure 48. Asia Large Molecule Drugs CDMO Revenue Share by Region (2021-2032) Figure 49. Japan Large Molecule Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Large Molecule Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Large Molecule Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Large Molecule Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Large Molecule Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Large Molecule Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Large Molecule Drugs CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Large Molecule Drugs CDMO Revenue Share by Type (2021-2032) Figure 57. SAMEA Large Molecule Drugs CDMO Revenue Share by Application (2021-2032) Figure 58. SAMEA Large Molecule Drugs CDMO Revenue Share by Country (2021-2032) Figure 59. Brazil Large Molecule Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Large Molecule Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Large Molecule Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Large Molecule Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Large Molecule Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Large Molecule Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Large Molecule Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Large Molecule Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Large Molecule Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Large Molecule Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Large Molecule Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Cell Line Development
  • Large Molecule Drug Substance Development
Applications
  • Biological Technology
  • Clinical
  • Pharmaceutical
  • Others
Companies covered
  • Patheon
  • Eurofins Scientific
  • Samsung Biologics
  • Catalent, Inc.
  • Rentschler Biopharma SE
  • AGC Biologics
  • Recipharm AB
  • Siegfried Holding AG
  • FUJIFILM Diosynth Biotechnologies
  • Scorpius
  • Ardena
  • Alcami
  • Cytiva
  • Thermo Fisher Scientific

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Large Molecule Drugs CDMO Market by Type
  3. 1.2.1 Global Large Molecule Drugs CDMO Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Cell Line Development
  5. 1.2.3 Large Molecule Drug Substance Development
  6. 1.3 Large Molecule Drugs CDMO Market by Application
  7. 1.3.1 Global Large Molecule Drugs CDMO Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Biological Technology
  9. 1.3.3 Clinical
  10. 1.3.4 Pharmaceutical
  11. 1.3.5 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Large Molecule Drugs CDMO Market Dynamics
  1. 2.1 Large Molecule Drugs CDMO Industry Trends
  2. 2.2 Large Molecule Drugs CDMO Industry Drivers
  3. 2.3 Large Molecule Drugs CDMO Industry Opportunities and Challenges
  4. 2.4 Large Molecule Drugs CDMO Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Large Molecule Drugs CDMO Market Perspective (2021-2032)
  2. 3.2 Global Large Molecule Drugs CDMO Growth Trends by Region
  3. 3.2.1 Global Large Molecule Drugs CDMO Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Large Molecule Drugs CDMO Market Size by Region (2021-2026)
  5. 3.2.3 Global Large Molecule Drugs CDMO Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Large Molecule Drugs CDMO Revenue by Players
  2. 4.1.1 Global Large Molecule Drugs CDMO Revenue by Players (2021-2026)
  3. 4.1.2 Global Large Molecule Drugs CDMO Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Large Molecule Drugs CDMO Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Large Molecule Drugs CDMO Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Large Molecule Drugs CDMO Key Players Headquarters & Area Served
  7. 4.4 Global Large Molecule Drugs CDMO Players, Product Type & Application
  8. 4.5 Global Large Molecule Drugs CDMO Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Large Molecule Drugs CDMO Market CR5 and HHI
  11. 4.6.3 2025 Large Molecule Drugs CDMO Tier 1, Tier 2, and Tier 3
5 Large Molecule Drugs CDMO Market Size by Type
  1. 5.1 Global Large Molecule Drugs CDMO Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Large Molecule Drugs CDMO Revenue by Type (2021-2032)
  3. 5.3 Global Large Molecule Drugs CDMO Revenue Market Share by Type (2021-2032)
6 Large Molecule Drugs CDMO Market Size by Application
  1. 6.1 Global Large Molecule Drugs CDMO Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Large Molecule Drugs CDMO Revenue by Application (2021-2032)
  3. 6.3 Global Large Molecule Drugs CDMO Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Patheon
  2. 7.1.1 Patheon Company Information
  3. 7.1.2 Patheon Business Overview
  4. 7.1.3 Patheon Large Molecule Drugs CDMO Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Patheon Large Molecule Drugs CDMO Product Portfolio
  6. 7.1.5 Patheon Recent Developments
  7. 7.2 Eurofins Scientific
  8. 7.2.1 Eurofins Scientific Company Information
  9. 7.2.2 Eurofins Scientific Business Overview
  10. 7.2.3 Eurofins Scientific Large Molecule Drugs CDMO Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Eurofins Scientific Large Molecule Drugs CDMO Product Portfolio
  12. 7.2.5 Eurofins Scientific Recent Developments
  13. 7.3 Samsung Biologics
  14. 7.3.1 Samsung Biologics Company Information
  15. 7.3.2 Samsung Biologics Business Overview
  16. 7.3.3 Samsung Biologics Large Molecule Drugs CDMO Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Samsung Biologics Large Molecule Drugs CDMO Product Portfolio
  18. 7.3.5 Samsung Biologics Recent Developments
  19. 7.4 Catalent, Inc.
  20. 7.4.1 Catalent, Inc. Company Information
  21. 7.4.2 Catalent, Inc. Business Overview
  22. 7.4.3 Catalent, Inc. Large Molecule Drugs CDMO Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Catalent, Inc. Large Molecule Drugs CDMO Product Portfolio
  24. 7.4.5 Catalent, Inc. Recent Developments
  25. 7.5 Rentschler Biopharma SE
  26. 7.5.1 Rentschler Biopharma SE Company Information
  27. 7.5.2 Rentschler Biopharma SE Business Overview
  28. 7.5.3 Rentschler Biopharma SE Large Molecule Drugs CDMO Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Rentschler Biopharma SE Large Molecule Drugs CDMO Product Portfolio
  30. 7.5.5 Rentschler Biopharma SE Recent Developments
  31. 7.6 AGC Biologics
  32. 7.6.1 AGC Biologics Company Information
  33. 7.6.2 AGC Biologics Business Overview
  34. 7.6.3 AGC Biologics Large Molecule Drugs CDMO Revenue and Gross Margin (2021-2026)
  35. 7.6.4 AGC Biologics Large Molecule Drugs CDMO Product Portfolio
  36. 7.6.5 AGC Biologics Recent Developments
  37. 7.7 Recipharm AB
  38. 7.7.1 Recipharm AB Company Information
  39. 7.7.2 Recipharm AB Business Overview
  40. 7.7.3 Recipharm AB Large Molecule Drugs CDMO Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Recipharm AB Large Molecule Drugs CDMO Product Portfolio
  42. 7.7.5 Recipharm AB Recent Developments
  43. 7.8 Siegfried Holding AG
  44. 7.8.1 Siegfried Holding AG Company Information
  45. 7.8.2 Siegfried Holding AG Business Overview
  46. 7.8.3 Siegfried Holding AG Large Molecule Drugs CDMO Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Siegfried Holding AG Large Molecule Drugs CDMO Product Portfolio
  48. 7.8.5 Siegfried Holding AG Recent Developments
  49. 7.9 FUJIFILM Diosynth Biotechnologies
  50. 7.9.1 FUJIFILM Diosynth Biotechnologies Company Information
  51. 7.9.2 FUJIFILM Diosynth Biotechnologies Business Overview
  52. 7.9.3 FUJIFILM Diosynth Biotechnologies Large Molecule Drugs CDMO Revenue and Gross Margin (2021-2026)
  53. 7.9.4 FUJIFILM Diosynth Biotechnologies Large Molecule Drugs CDMO Product Portfolio
  54. 7.9.5 FUJIFILM Diosynth Biotechnologies Recent Developments
  55. 7.10 Scorpius
  56. 7.10.1 Scorpius Company Information
  57. 7.10.2 Scorpius Business Overview
  58. 7.10.3 Scorpius Large Molecule Drugs CDMO Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Scorpius Large Molecule Drugs CDMO Product Portfolio
  60. 7.10.5 Scorpius Recent Developments
  61. 7.11 Ardena
  62. 7.11.1 Ardena Company Information
  63. 7.11.2 Ardena Business Overview
  64. 7.11.3 Ardena Large Molecule Drugs CDMO Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Ardena Large Molecule Drugs CDMO Product Portfolio
  66. 7.11.5 Ardena Recent Developments
  67. 7.12 Alcami
  68. 7.12.1 Alcami Company Information
  69. 7.12.2 Alcami Business Overview
  70. 7.12.3 Alcami Large Molecule Drugs CDMO Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Alcami Large Molecule Drugs CDMO Product Portfolio
  72. 7.12.5 Alcami Recent Developments
  73. 7.13 Cytiva
  74. 7.13.1 Cytiva Company Information
  75. 7.13.2 Cytiva Business Overview
  76. 7.13.3 Cytiva Large Molecule Drugs CDMO Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Cytiva Large Molecule Drugs CDMO Product Portfolio
  78. 7.13.5 Cytiva Recent Developments
  79. 7.14 Thermo Fisher Scientific
  80. 7.14.1 Thermo Fisher Scientific Company Information
  81. 7.14.2 Thermo Fisher Scientific Business Overview
  82. 7.14.3 Thermo Fisher Scientific Large Molecule Drugs CDMO Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Thermo Fisher Scientific Large Molecule Drugs CDMO Product Portfolio
  84. 7.14.5 Thermo Fisher Scientific Recent Developments
8 North America
  1. 8.1 North America Large Molecule Drugs CDMO Revenue (2021-2032)
  2. 8.2 North America Large Molecule Drugs CDMO Revenue by Type (2021-2032)
  3. 8.2.1 North America Large Molecule Drugs CDMO Revenue by Type (2021-2026)
  4. 8.2.2 North America Large Molecule Drugs CDMO Revenue by Type (2027-2032)
  5. 8.3 North America Large Molecule Drugs CDMO Revenue Share by Type (2021-2032)
  6. 8.4 North America Large Molecule Drugs CDMO Revenue by Application (2021-2032)
  7. 8.4.1 North America Large Molecule Drugs CDMO Revenue by Application (2021-2026)
  8. 8.4.2 North America Large Molecule Drugs CDMO Revenue by Application (2027-2032)
  9. 8.5 North America Large Molecule Drugs CDMO Revenue Share by Application (2021-2032)
  10. 8.6 North America Large Molecule Drugs CDMO Revenue by Country
  11. 8.6.1 North America Large Molecule Drugs CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Large Molecule Drugs CDMO Revenue by Country (2021-2026)
  13. 8.6.3 North America Large Molecule Drugs CDMO Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Large Molecule Drugs CDMO Revenue (2021-2032)
  2. 9.2 Europe Large Molecule Drugs CDMO Revenue by Type (2021-2032)
  3. 9.2.1 Europe Large Molecule Drugs CDMO Revenue by Type (2021-2026)
  4. 9.2.2 Europe Large Molecule Drugs CDMO Revenue by Type (2027-2032)
  5. 9.3 Europe Large Molecule Drugs CDMO Revenue Share by Type (2021-2032)
  6. 9.4 Europe Large Molecule Drugs CDMO Revenue by Application (2021-2032)
  7. 9.4.1 Europe Large Molecule Drugs CDMO Revenue by Application (2021-2026)
  8. 9.4.2 Europe Large Molecule Drugs CDMO Revenue by Application (2027-2032)
  9. 9.5 Europe Large Molecule Drugs CDMO Revenue Share by Application (2021-2032)
  10. 9.6 Europe Large Molecule Drugs CDMO Revenue by Country
  11. 9.6.1 Europe Large Molecule Drugs CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Large Molecule Drugs CDMO Revenue by Country (2021-2026)
  13. 9.6.3 Europe Large Molecule Drugs CDMO Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Large Molecule Drugs CDMO Revenue (2021-2032)
  2. 10.2 China Large Molecule Drugs CDMO Revenue by Type (2021-2032)
  3. 10.2.1 China Large Molecule Drugs CDMO Revenue by Type (2021-2026)
  4. 10.2.2 China Large Molecule Drugs CDMO Revenue by Type (2027-2032)
  5. 10.3 China Large Molecule Drugs CDMO Revenue Share by Type (2021-2032)
  6. 10.4 China Large Molecule Drugs CDMO Revenue by Application (2021-2032)
  7. 10.4.1 China Large Molecule Drugs CDMO Revenue by Application (2021-2026)
  8. 10.4.2 China Large Molecule Drugs CDMO Revenue by Application (2027-2032)
  9. 10.5 China Large Molecule Drugs CDMO Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Large Molecule Drugs CDMO Revenue (2021-2032)
  2. 11.2 Asia Large Molecule Drugs CDMO Revenue by Type (2021-2032)
  3. 11.2.1 Asia Large Molecule Drugs CDMO Revenue by Type (2021-2026)
  4. 11.2.2 Asia Large Molecule Drugs CDMO Revenue by Type (2027-2032)
  5. 11.3 Asia Large Molecule Drugs CDMO Revenue Share by Type (2021-2032)
  6. 11.4 Asia Large Molecule Drugs CDMO Revenue by Application (2021-2032)
  7. 11.4.1 Asia Large Molecule Drugs CDMO Revenue by Application (2021-2026)
  8. 11.4.2 Asia Large Molecule Drugs CDMO Revenue by Application (2027-2032)
  9. 11.5 Asia Large Molecule Drugs CDMO Revenue Share by Application (2021-2032)
  10. 11.6 Asia Large Molecule Drugs CDMO Revenue by Country
  11. 11.6.1 Asia Large Molecule Drugs CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Large Molecule Drugs CDMO Revenue by Country (2021-2026)
  13. 11.6.3 Asia Large Molecule Drugs CDMO Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Large Molecule Drugs CDMO Revenue (2021-2032)
  2. 12.2 SAMEA Large Molecule Drugs CDMO Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Large Molecule Drugs CDMO Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Large Molecule Drugs CDMO Revenue by Type (2027-2032)
  5. 12.3 SAMEA Large Molecule Drugs CDMO Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Large Molecule Drugs CDMO Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Large Molecule Drugs CDMO Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Large Molecule Drugs CDMO Revenue by Application (2027-2032)
  9. 12.5 SAMEA Large Molecule Drugs CDMO Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Large Molecule Drugs CDMO Revenue by Country
  11. 12.6.1 SAMEA Large Molecule Drugs CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Large Molecule Drugs CDMO Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Large Molecule Drugs CDMO Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst